Form 4: Cytokinetics Director Sells Shares After Option Exercise

Cytokinetics Director Wendell Wierenga exercised stock options and subsequently sold a portion of his common stock holdings under a 10b5-1 plan.

Summary

• Wendell Wierenga, a Director of Cytokinetics Inc. (CYTK), executed a transaction on December 22, 2025.
• Wierenga exercised 20,000 Non-Qualified Stock Options at an exercise price of $7.61 per share.
• Immediately following the exercise, Wierenga sold 20,000 shares of Common Stock at a price of $66.14 per share.
• These transactions were conducted pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• After these reported transactions, Wierenga directly beneficially owns 32,444 shares of Common Stock.

Sentiment

Score: 5

Explanation: Neutral, as this Form 4 reports a routine insider transaction (exercise and sell) often pre-scheduled under a 10b5-1 plan. The transaction itself does not inherently reflect a positive or negative outlook for the company, though the significant gain for the insider is notable.

Positives

• The director realized a significant gain, selling shares at $66.14 after exercising options at $7.61, indicating a substantial profit from the compensation package.

Negatives

• A director sold 20,000 shares of common stock, which reduces their direct equity stake in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May observe the director's stock activity, which is a routine compensation-related transaction and often pre-scheduled, thus typically not indicating a change in company fundamentals.

Key Dates

Keywords

Cytokinetics, CYTK, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director Transaction, Wendell Wierenga, 10b5-1 Plan